Lipid-lowering medications

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 1, 2004, Pages 171-180

  Rodenburg, Jessica ^a   Vissers, Maud N ^a   Daniels, Stephen R ^b   Wiegman, Albert ^a   Kastelein, John J P ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Cincinnati Children's Hosp Med C   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bile acid bindins resins; Ezetimibe; Fibrates; Nicotinic acid; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CIPROFIBRATE; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ARTHRALGIA; BLOATING; BODY WEIGHT DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRY SKIN; DYSLIPIDEMIA; DYSPEPSIA; FATIGUE; FLATULENCE; FLUSHING; GALLSTONE; GOUT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERURICEMIA; INTESTINE DISTENSION; LIFESTYLE; LIVER TOXICITY; MONOTHERAPY; MOOD DISORDER; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRURITUS; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SLEEP DISORDER; SUSTAINED RELEASE FORMULATION; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VITAMIN DEFICIENCY; VOMITING; WEIGHT REDUCTION;

ADULT; ANTICHOLESTEREMIC AGENTS; CHILD; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 12344326571     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Goldstein JL, Hobbs HH, Brown HS. Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The metabolic Basis of Inherited Disease. New York, USA: McGraw-Hill 2001:2863-913
2. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:525-584
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
4. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980;2:873-875
5. Farah JR, Kwiterovich PO, Jr, Neill CA. Dose-effect relation of cholestyramine in children and young adults with familial hypercholesterolaemia. Lancet 1977;1:59-63
6. Groot PH, Dijkhuis-Stoffelsma R, Grose WF, Ambagtsheer JJ, Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand 1983;72:81-85
7. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989;9:I145-I151
8. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics 1980;65:243-250
9. Schlierf G, Mrozik K, Heuck CC, Middelhoff G, Oster P, Riesen W, Schellenbers B. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia. Atherosclerosis 1982;41:133-138
10. Glueck CJ, Mellies MJ, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics 1986;78:338-348
11. Hennermann JB, Herwig J, Marz W, Asskali F, Bohles HJ. Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Eur J Pediatr 1998;157:912-918
12. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996;129:42-49
13. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child 1996;74:157-160
14. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997;130:266-273
15. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907
16. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-98
17. Hansen D, Michaelsen KF, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Paediatr 1992;81:1023-1025
18. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr 1992;81:682-685
19. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 1996;85:1080-1082
20. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams and Wilkins, 2002
21. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res 2000;87:946-952
22. Athyros VG, Papageorgiou AA, Kontopoulos AG. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163:205-206
23. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143:74-80
24. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin O, Lambert J. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996;97:619-628
25. Stein EA, Illingworth DR, Kwiterovich PO, Jr., Liacouras CA, Siimes MA, Jacobson MS, Brewster TC, Hopkins P, Davidson M, Graham K, Arensman, F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial [see comments]. JAMA 1999;281:137-144
26. Kwiterovich PO, Jr. Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. Nutr Metab Cardiovasc Dis 2001;11(Suppl 5):30-34.
27. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer, BE, van den EA, Buller HR, Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia [published erratum appears in Pediatr Res 1996 Dec;40(6):866]. Pediatr Res 1996;39:867-871
28. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer, BE, van den EA, Buller HR, Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia [published erratum appears in Pediatr Res 1996 Dec;40(6):866]. Pediatr Res 1996;39:867-871
29. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJP. Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia: a Randomized Controlled Trial. JAMA 2004;292:331-337
30. Couture P, Brun LD, Szots F, Lelievre M, Gaudet D, Despres JP, Simard J, Lupien PJ, Gagne C. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:1007-1012
31. Ducobu J, Brasseur D, Chaudron JM, Deslypere JP, Harvengt C, Muls E, Thomson M. Simvastatin use in children. Lancet 1992;339:1488
32. de Jongn S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-2237
33. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr 2003;162:421-425
34. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-564
35. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-295
36. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N End J Med 2002;346:539-540
37. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-127
38. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-483
39. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402
40. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996;10:439-446
41. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004;350:1579-1582
42. Henck JW, Craft WR, Black A, Colgin J, Anderson JA. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci 1998;41:88-99
43. Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001;8:187-194
44. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987;83:9-20
45. de Man FH, de Beer F, van der LA, Jansen H, Leuven JA, Souverijn JH, Vroom TF, Schoormans SC, Fruchart JC, Havekes LM, Smelt AH. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis 2000;153:363-371
46. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981;112:43
47. Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985;60:34-37
48. Becker M, Staab D, Von Bergman K. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics 1992;89:138-142
49. Matzno S, Tazuya-Murayama K, Tanaka H, Yasuda S, Mishima M, Uchida T, Nakabayashi T, Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 2003;55:795-802
50. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001;21:1783-1789
51. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-2028
52. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000;86:35L-40L
53. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-1104
54. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998;82:29U-34U
55. Goldberg A, Alagona P, Jr., Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management or hyperlipidemia. Am J Cardiol 2000;85:1100-1105
56. Grundy SM, Vega GL McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-1576
57. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82
58. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86:51L-56L
59. Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204
60. Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc Natl Acad Sci U S A 2004;101:3450-3455
61. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR, Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-1754
62. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-437
63. Zhu Y, Statkevich P, Zambas D, Patrick J, Cayen MN, Batra V. Effect of SCH 58235 on the activity of drug metabolzing enzymes in vivo. Clin Pharmacol Ther 2004;67:152 (abstr)
64. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-1948
65. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, LeBeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-1230
66. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP. Suresh R, Yang B, Veltri EP. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-741
67. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90;1092-1097
68. Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-971
69. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003;25:2352-2387
70. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124-3128